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Several psychiatric disorders have been
associated with 22q11.2 deletion syndrome
(22q11.2DS) also known as VeloCardioFacial
Syndrome (VCFS) or Di George Syndrome. The
identification of the cause of 22q11.2DS dates
back to more than twenty years ago and since
then, a substantial number of papers have
been written on the association between VCFS
and psychiatric disorders.1
The most frequent psychiatric disorders
associated with 22q11.2DS are schizophrenia-
like psychoses and their risk has been reported
even up to 25 times than in general population.
Among 22q11.2DS children, frequent diag-
noses are autism-spectrum disorders and
attention deficit/hyperactivity disorders, in
adolescents and adults about 30% develop
schizophrenia-like psychoses. The close asso-
ciation between 22q11.2DS and schizophrenia-
like psychoses, has been considered as an
excellent model to better understand brain dys-
function, social cognition, psychotic symptoms
and cognitive and behavioral impairments. 
The disease has similar prevalence and
developmental patterns across countries. Data
from an Israel and Switzerland large sample of
22q11DS, show that the average age at onset of
schizophrenia-like psychoses ranges from19 to
26 years.2 Moreover, psychotic-like symptoms
were observed in almost one third of 22q11DS
adolescents. Knowing the high risk for schizo-
phrenia-like psychosis in 22q11.2DS subjects,
the early identification of who will develop psy-
chosis would be crucial for therapeutic pro-
grams. Antshel et al.,3 in their 3-year follow-up
study, showed that the most significant predic-
tors of adolescent prodromal psychotic symp-
toms were parent ratings of odd/eccentric
symptoms and lower performance on the per-
severative errors at the Wisconsin Card
Sorting Test.
When 22q11.2DS subjects with psychoses
need a psychopharmacological treatment, the
antipsychotic therapies need to bee carefully
chosen, taking into account literature data on
efficacy and tolerability. 22q11.2DS subjects
seem to have a higher susceptibility to side
effects when on antipsychotic therapies than
subjects with psychotic disorders (without the
22q11.2DS). In the case report by
Kontoangelos et al.4, a severe acute dystonia
was reported in a subject on a low dosage of
Haloperidol and had a good tolerability to que-
tiapine. In an other very recent paper, Butcher
et al.,5 show that 22q11.2DS schizophrenia
subjects are at higher risk for severe side
effects when on Clozapine, although they had
a good clinical response. Further data on cloza-
pine and quetiapine efficacy in 22q11.2DS sub-
jects with relapsing psychoses, are presented
by Vorhoeven and Egger.6 The two atypical
antipsychotics in combination with valproic
acid, seem more effective than other therapies
in their treatment resistant patients’ sample
The early-onset Parkinson’s disease,7 of the
22q11DS phenotype in older adults, is a rele-
vant and clinically intriguing data. This pheno-
type has now been described in multiple case
reports, suggesting that dopaminergic disrup-
tion in 22q11DS may be relevant to the expres-
sion of both psychosis and Parkinson’s disease
over the life span. These data may suggest a
hypothetical explanation of the increased sen-
sitivity to antipsychotics’ side effects in
22q11.2DS subjects.
The data currently available on 22q11.2DS,
are really promising for further comprehen-
sion of that fascinating subject of study which
are psychoses and schizophrenia.
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